GATA1 and hepatocellular carcinoma: Most (56%) patients showed the homozygous ‐1573TT genotype at position ‐1573 of the TRAIL promoter in the HCC tissue with a functional in silico GATA‐1‐binding site, whereas 28% of the patients exhibited a heterozygous genotype (‐1573 TC) at this position and only 16% of the patients showed the homozygous ‐1573 CC genotype with the complete loss‐of‐function mutation.